Trulieve Cannabis Corp.

TRLV ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-122.2M $-160.6M $-533.1M $-252.7M $17.4M $63.0M $53.1M
Depreciation & Amortization $117.6M $112.8M $109.8M $116.4M $45.8M $12.6M $5.1M
Depreciation — — — $76.4M $34.8M $21.1M $9.3M
Amortization $83.3M $82.2M $80.4M $81.7M $27.7M $3.0M $1.8M
Stock-Based Compensation $20.5M $20.2M $10.6M $18.1M $9.3M $2.8M —
Net Cash from Operating Activities $272.8M $271.5M $201.8M $23.1M $12.9M $99.6M $19.1M
Investing Activities
Capital Expenditures $44.2M $122.6M $40.2M $164.7M $275.9M $99.9M $71.8M
Business Acquisitions — $0 $0 $27.8M $-43.5M $27.9M $19.8M
Net Cash from Investing Activities $13.5M $-206.6M $-37.5M $-215.1M $-215.2M $-174.7M $-94.7M
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $-270.5M $-33.4M $-175.6M $177.8M $289.2M $129.9M $143.0M
Net Change in Cash $15.8M $31.4M $-11.2M $-14.2M $86.9M $54.9M $67.4M
Free Cash Flow $228.6M $148.9M $161.6M $-141.7M $-263.0M $-298.0K $-52.8M